arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

GYRE THERAPEUTICS, INC.

GYRE
$6.65 ▲ +0.24 (+3.74%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
50
Health
Fair
Neutral
auto_awesome

Analytical Summary

GYRE THERAPEUTICS, INC. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $607.3M
Dividend Yield
Revenue Growth 2.1%
Op. Margin -41.5%
ROIC -9.9%
FCF / Share $0.03
Trailing P/E
Price / Book 6.0x
FCF Yield 0.5%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$22.52M
↑ +2.1%
Net Income Profit after all expenses
$-9.86M
↓ -646.8%
Operating Margin Operating profit as % of sales
-41.5%
↓ -13194.8% 56th
FCF / Share Free cash flow per share
$0.03
↓ -25.5%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%

Health Breakdown

Profitability
47
Returns
66
Cash Quality
21

Dividend History

Dividend / share · sourced from SEC filings
$0.24 Latest / share
-83.2% YoY

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters